Diabetic – Gerfa Labs

Diabetic

Daposit-M Tab

Brand Name: Daposit-M™ Tab
Generic Name: Dapagliflozin 10 mg + Sitagliptin 100 mg + Metformin (Extended Release) 500 mg (Fixed-dose combination)
Dosage Forms: Oral Tablet
Composition of Daposit-M™: Dapagliflozin: 10 mg (Sodium-glucose cotransporter 2 [SGLT2] inhibitor). Sitagliptin: 100 mg (Dipeptidyl peptidase-4 [DPP-4] inhibitor). Metformin Hydrochloride (Extended Release): 500 mg (Biguanide).

Combined Mechanism of Action:

Daposit-M™ provide a multi-pronged approach to controlling blood glucose levels:

Dapagliflozin helps with basal glucose control and weight reduction.
Sitagliptin improves insulin response to meals and controls hepatic glucose production.
Voglibose controls postprandial blood sugar increases, complementing the other drugs.

This combination is beneficial in controlling both fasting and postprandial blood glucose levels in individuals with type 2 diabetes.

Indications: Daposit-M™

Indicated for the treatment of type 2 diabetes mellitus

Packaging:

Each Alu-Alu strip Daposit-M™ contains 10 tablets.

Glyvom 80.2 mg Tab

Brand Name: Glyvom 80.2™
Generic Name: Gliclazide 80 mg + Metformin 500 mg + Voglibose 0.2 mg (Fixed-dose combination)
Dosage Forms: Oral Tablet
Composition of Glyvom 80.2™: Gliclazide: 80 mg (an oral sulfonylurea). Metformin Hydrochloride: 500 mg (a biguanide). Voglibose: 0.2 mg (an α-glucosidase inhibitor).

Combined mechanism of action:

Gliclazide: Stimulates insulin release from the pancreas.
Metformin: Reduces hepatic glucose production and improves insulin sensitivity.
Voglibose: Inhibits intestinal enzymes that break down carbohydrates, slowing glucose absorption.

Indications of Glyvom 80.2™:

Glyvom 80.2 is indicated for the treatment of type 2 diabetes mellitus (non-insulin-dependent diabetes)

Packaging:

Each Alu-Alu strip of Glyvom-80.2™ contains 10 tablets.

Glydap-M Tab

Brand Name: Glydap-M
Generic Name: Dapagliflozin 10 mg + Metformin (Extended Release) 500 mg (Fixed-dose combination)
Dosage Form: Oral Tablet
Composition of Glydap-M: Dapagliflozin: 10 mg + Metformin Hydrochloride (Extended Release): 500 mg

Combined Mechanism of Action :

Dapagliflozin (SGLT2 inhibitor) reduces blood glucose by increasing urinary glucose excretion.
Metformin (Biguanide) lowers blood glucose by reducing hepatic glucose production and improving insulin sensitivity.

This combination is effective in controlling both fasting and postprandial blood glucose levels and provides a multifaceted approach to managing type 2 diabetes.

Indications:

Dapagliflozin 10 mg + Metformin (ER) 500 mg is indicated for the treatment of type 2 diabetes mellitus:
To improve glycemic control in adult patients, along with diet and exercise.
In patients who are inadequately controlled on Metformin alone or Dapagliflozin alone.
Can be used as part of a treatment regimen with other antidiabetic agents, including insulin, if needed.

Packaging:

Each Alu-Alu strip of Glydap-M contains 10 tablets.

Villa-M Tab

Brand Name: Villa-M
Generic Name: Vildagliptin + Metformin (Fixed-dose combination)
Dosage Form: Oral Tablet
Composition of Villa-M: • Vildagliptin: 50 mg + Metformin Hydrochloride: 500 mg

Mechanism of Action:

Vildagliptin enhances insulin release when glucose levels are high and reduces excess glucose production from the liver.
Metformin works to improve insulin sensitivity and reduce glucose production from the liver, further controlling blood sugar levels.

This combination is effective in improving both fasting and postprandial blood glucose levels in patients with type 2 diabetes.

Indications of Villa-M:

Vildagliptin 50 mg + Metformin 500 mg is indicated for the treatment of type 2 diabetes mellitus:
As an adjunct to diet and exercise to improve glycemic control.
In patients who are inadequately controlled on Metformin alone or Vildagliptin alone.
In combination with other oral antidiabetic agents if needed.

Packaging:

Each Alu-Alu strip of Villa-M contains 10 tablets.